跳转至

思维减速

◀返回

思维减速（也被称为思维迟缓）[1]指的是与正常的清醒状态相比，思维过程显著变慢的过程哦。当体验这种效应时，会感觉产生一个念头所需的时间，以及每个念头之间的时间间隔都被拉长了，以至于严重损害了认知过程呢。它可能表现为识别延迟、反应时间变慢和精细运动技能缺陷。

思维减速通常伴随着其他并发效应，比如分析能力抑制和镇静，这不仅降低了人的思维速度，也显著降低了人精神清晰度的敏锐度。它最常在严重剂量的抑制剂类化合物影响下被诱发，比如GABA类药物[2][3][4]、抗精神病药[5]和阿片类药物[6][7][8]呢。然而，在严重剂量的致幻剂影响下，它也可能在较小程度上发生，比如迷幻剂[9]、解离剂[10]、谵妄剂[4][11]和大麻类物质[12][13][14][15]嘛。

目录

体验报告

在我们的体验报告索引中，描述了这种效应的轶事报告包括：

  • Experience: 22mg 2C-B (oral) / 100ug 1P-LSD (sublingual) - My first time tripping alone (2 days in a row)/_100ug_1P-LSD(sublingual)-_My_first_time_tripping_alone(2_days_in_a_row).md)
  • Experience:3-MEO-PCMo (420mg) - Trip Report_-_Trip_Report.md)
  • Experience:3g Syrian Rue + 5g Acacia Confusa - Life Changing Madness
  • Experience:3mg Etizolam - A Comedown Drug
  • Experience:4 Days Sleep Deprivation - Progression of Sleep Deprivation Visuals Over Time
  • Experience:75mg DMT - Experiencing Death
  • Experience:DXM and Cannabis: 100mg - Unexpected Strong Trip
  • Experience:MXE: 37.5 mg - Calm and Cloudy Bliss
  • Experience:Psilocybin Mushroom (0.16 g, Oral) - Dosage Independent Intensity_-_Dosage_Independent_Intensity.md)
  • Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death_-_Overdosing_and_Terifying_Ego_Death.md)
  • Experience:~150mg MDA(oral) - a case of mistaken identity_-_a_case_of_mistaken_identity.md)

另见

外部链接

参考文献

  1. ↑ Levin, E (1996). "Nicotine-Haloperidol Interactions and Cognitive Performance in Schizophrenics". Neuropsychopharmacology. 15 (5): 429–436. doi:10.1016/S0893-133X(96)00018-8. ISSN 0893-133X.
  2. ↑ Vermeeren, A.; Muntjewerff, N. D.; Quint, P. J.; O'Hanlon, J. F.; Jackson, J. L.; Harrison, E. M. (1995). "Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests". Psychopharmacology. 118 (1): 1–9. doi:10.1007/BF02245243. ISSN 0033-3158.
  3. ↑ Johannes, Sönke; Wieringa, Bernardina M.; Nager, Wido; Dengler, Reinhard; Münte, Thomas F. (2001). "Oxazepam alters action monitoring". Psychopharmacology. 155 (1): 100–106. doi:10.1007/s002130100680. ISSN 0033-3158.
  4. ↑ 4.0 4.1 Semlitsch, H.V.; Anderer, P.; Saletu, B. (1995). "Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects". European Journal of Clinical Pharmacology. 49 (3). doi:10.1007/BF00192378. ISSN 0031-6970.
  5. ↑ Naber, Dieter (2011). "Subjective effects of antipsychotic drugs and their relevance for compliance and remission". Epidemiologia e Psichiatria Sociale. 17 (03): 174–176. doi:10.1017/S1121189X00001238. ISSN 1121-189X.
  6. ↑ Kurita, Geana Paula; Lundorff, Lena; Pimenta, Cibele Andrucioli de Mattos; Sjøgren, Per (2008). "The cognitive effects of opioids in cancer: a systematic review". Supportive Care in Cancer. 17 (1): 11–21. doi:10.1007/s00520-008-0497-y. ISSN 0941-4355.
  7. ↑ Twillman, Robert K; Long, Teresa D; Cathers, Teresa A; Mueller, David W (1999). "Treatment of Painful Skin Ulcers with Topical Opioids". Journal of Pain and Symptom Management. 17 (4): 288–292. doi:10.1016/S0885-3924(98)00140-7. ISSN 0885-3924.
  8. ↑ Ersek, Mary; Cherrier, Monique M; Overman, Steven S; Irving, Gordon A (2004). "The cognitive effects of opioids". Pain Management Nursing. 5 (2): 75–93. doi:10.1016/j.pmn.2003.11.002. ISSN 1524-9042.
  9. ↑ Kaelen, Mendel; Giribaldi, Bruna; Raine, Jordan; Evans, Lisa; Timmerman, Christopher; Rodriguez, Natalie; Roseman, Leor; Feilding, Amanda; Nutt, David; Carhart-Harris, Robin (2018). "The hidden therapist: evidence for a central role of music in psychedelic therapy". Psychopharmacology. 235 (2): 505–519. doi:10.1007/s00213-017-4820-5. ISSN 0033-3158.
  10. ↑ Freyd, Jennifer J.; Martorello, Susan R.; Alvarado, Jessica S.; Hayes, Amy E.; Christman, Jill C. (1998). "Cognitive environments and dissociative tendencies: performance on the standard Stroop task for high versus low dissociators". Applied Cognitive Psychology. 12 (7): S91–S103. doi:10.1002/(SICI)1099-0720(199812)12:7\<S91::AID-ACP599>3.0.CO;2-Z. ISSN 0888-4080.
  11. ↑ Nebes, Robert D.; Pollock, Bruce G.; Halligan, Edythe M.; Houck, Patricia; Saxton, Judith A. (2011). "Cognitive Slowing Associated With Elevated Serum Anticholinergic Activity in Older Individuals is Decreased by Caffeine Use". The American Journal of Geriatric Psychiatry. 19 (2): 169–175. doi:10.1097/JGP.0b013e3181e4490d. ISSN 1064-7481.
  12. ↑ Crean, Rebecca D.; Crane, Natania A.; Mason, Barbara J. (2011). "An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive Functions". Journal of Addiction Medicine. 5 (1): 1–8. doi:10.1097/ADM.0b013e31820c23fa. ISSN 1932-0620.
  13. ↑ Tapert, S., Schweinsburg, A., Brown, S. (1 January 2008). "The Influence of Marijuana Use on Neurocognitive Functioning in Adolescents". Current Drug Abuse Reviewse. 1 (1): 99–111. doi:10.2174/1874473710801010099. ISSN 1874-4737. Retrieved 4 June 2022.
  14. ↑ Bhattacharyya, Sagnik; Sendt, Kyra-Verena (2012). "Neuroimaging Evidence for Cannabinoid Modulation of Cognition and Affect in Man". Frontiers in Behavioral Neuroscience. 6. doi:10.3389/fnbeh.2012.00022. ISSN 1662-5153.
  15. ↑ Roberto, Aaron J.; Lorenzo, Aileen; Li, Kevin J.; Young, Jonathan; Mohan, Abhishek; Pinnaka, Subhash; Lapidus, Kyle A. B. (2016). "First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone". Case Reports in Psychiatry. 2016: 1–4. doi:10.1155/2016/7257489. ISSN 2090-682X.